肺癌脑转移MRI影像基因组学研究进展

doi:10.3969/j.issn.1674-490X.2022.01.004

摘要/Abstract

摘要： 脑转移瘤是发病率高且预后差的颅内恶性肿瘤,以肺癌脑转移在临床中最为常见。MRI作为颅内肿瘤首选影像诊断方法,MRI影像基因组学逐步应用于脑转移瘤的精准个体化诊疗。伴随着对基因与肿瘤之间联系的不断深入研究,肿瘤的诊断正向分子遗传学方向延伸,影像基因组学是一种将影像表型与基因分子融合的方法,运用无创精准的方式检测活体肿瘤的分子遗传学改变,在肿瘤的发现、指导治疗及预后预测等方面已广泛应用。现基于颅脑的MRI图像,对影像基因组学在肺癌脑转移应用的可行性及研究进展予以综述。

关键词: 肺癌, 脑转移, 磁共振成像, 影像组学, 基因

Abstract: Brain metastases are intracranial malignant tumors with high incidence and poor prognosis, brain metastases from lung cancer are the most common in clinical practice. MR is the preferred imaging diagnosis method for intracranial tumors, and MRI imagingomics is gradually applied to the precise and individualized diagnosis and treatment of brain metastases. With the continuous in-depth research on the connection between genes and tumors, tumor diagnosis is extended to the direction of molecular genetics. Radiogenomics is a method of fusing imaging phenotypes with genes and molecules, using non-invasive and accurate methods to detect tumors. The molecular genetic changes of the disease have been widely used in tumor discovery, treatment guidance and prognosis prediction, etc. This article reviews the feasibility and research progress of MRI radiogenomics radio genomics in brain metastases.

Key words: lung cancer, brain metastases, magnetic resonance imaging, radiomics, gene

中图分类号:

隋莲玉,殷小平,王佳宁. 肺癌脑转移MRI影像基因组学研究进展[J]. 医学研究与教育, 2022, 39(1): 25-34.

SUI Lianyu, YIN Xiaoping, WANG Jianing. Developments on radiogenomics based on MRI in lung cancer brain metastases[J]. Journal of Hebei Medical College for Continuing Education, 2022, 39(1): 25-34.

参考文献

[1] SIEGEL R L, MILLER K D, FUCHS H E, et al. Cancer statistics, 2021[J]. CA Cancer J Clin, 2021, 71(1): 7-33. DOI: 10.3322/caac.21654.
[2] 袁蕙芸,蒋宇飞,谭玉婷,等.全球癌症发病与死亡流行现状和变化趋势[J].肿瘤防治研究, 2021, 48(6): 642-646. DOI: 10.3971/j.issn.1000-8578.2021.20.1533.
[3] POPAT S, WELSH L. Brain metastases in solid tumours: new guidelines for a new era[J]. Ann Oncol, 2021, 32(11): 1322-1324. DOI: 10.1016/j.annonc.2021.08.1992.
[4] 中国医师协会肿瘤医师分会,中国医疗保健国际交流促进会肿瘤内科分会. Ⅳ期原发性肺癌中国治疗指南(2021年版)[J].中华肿瘤杂志, 2021, 43(1): 39-59. DOI: 10.3760/cma.j.cn112152-20201009-00884.
[5] FECCI P E, CHAMPION C D, HOJ J, et al. The evolving modern management of brain metastasis[J]. Clin Cancer Res, 2019, 25(22): 6570-6580. DOI: 10.1158/1078-0432.CCR-18-1624.
[6] BEKAERT L, EMERY E, LEVALLET G, et al. Histopathologic diagnosis of brain metastases: current trends in management and future considerations[J]. Brain Tumor Pathol, 2017, 34(1): 8-19. DOI: 10.1007/s10014-016-0275-3.
[7] GILLIES R J, KINAHAN P E, HRICAK H. Radiomics: images are more than pictures, they are data[J]. Radiology, 2016, 278(2): 563-577. DOI: 10.1148/radiol.2015151169.
[8] LAMBIN P, LEIJENAAR R T H, DEIST T M, et al. Radiomics: the bridge between medical imaging and personalized medicine[J]. Nat Rev Clin Oncol, 2017, 14(12): 749-762. DOI: 10.1038/nrclinonc.2017.141.
[9] QIAN Z H, LI Y M, WANG Y Z, et al. Differentiation of glioblastoma from solitary brain metastases using radiomic machine-learning classifiers[J]. Cancer Lett, 2019, 451: 128-135. DOI: 10.1016/j.canlet.2019.02.054.
[10] 吕建波,齐欣,陈志庚,等.基于MRI影像组学鉴别高级别胶质瘤和单发脑转移瘤的研究进展[J].磁共振成像, 2021, 12(6): 108-110. DOI: 10.12015/issn.1674-8034.2021.06.022.
[11] ORTIZ-RAMÓN R, LARROZA A, RUIZ-ESPAÑA S, et al. Classifying brain metastases by their primary site of origin using a radiomics approach based on texture analysis: a feasibility study[J]. Eur Radiol, 2018, 28(11): 4514-4523. DOI: 10.1007/s00330-018-5463-6.
[12] KNIEP H C, MADESTA F, SCHNEIDER T, et al. Radiomics of brain MRI: utility in prediction of metastatic tumor type[J]. Radiology, 2019, 290(2): 479-487. DOI: 10.1148/radiol.2018180946.
[13] LARROZA A, MORATAL D, PAREDES-SÁNCHEZ A, et al. Support vector machine classification of brain metastasis and radiation necrosis based on texture analysis in MRI[J]. J Magn Reson Imaging, 2015, 42(5): 1362-1368. DOI: 10.1002/jmri.24913.
[14] WANG H S, XUE J Y, QU T X, et al. Predicting local failure of brain metastases after stereotactic radiosurgery with radiomics on planning MR images and dose maps[J]. Med Phys, 2021, 48(9): 5522-5530. DOI: 10.1002/mp.15110.
[15] 熊飞,王叶,王翅鹏,等.ADC直方图鉴别脑转移瘤病理性质的价值[J].中国临床神经外科杂志, 2018, 23(7): 452-454. DOI: 10.13798/j.issn.1009-153X.2018.07.002.
[16] LI Z J, MAO Y, LI H S, et al. Differentiating brain metastases from different pathological types of lung cancers using texture analysis of T1 postcontrast MR[J]. Magn Reson Med, 2016, 76(5): 1410-1419. DOI: 10.1002/mrm.26029.
[17] 李瑞,葛亚琼,张明珠,等.基于全肿瘤区域MRI纹理分析鉴别肺癌脑转移瘤病理类型的研究[J].放射学实践, 2021, 36(2): 176-180. DOI: 10.13609/j.cnki.1000-0313.2021.02.006.
[18] ZHANG J, JIN J B, AI Y, et al. Differentiating the pathological subtypes of primary lung cancer for patients with brain metastases based on radiomics features from brain CT images[J]. Eur Radiol, 2021, 31(2): 1022-1028. DOI: 10.1007/s00330-020-07183-z.
[19] KARAMI E, SOLIMAN H, RUSCHIN M, et al. Quantitative MRI biomarkers of stereotactic radiotherapy outcome in brain metastasis[J]. Sci Rep, 2019, 9(1): 19830. DOI: 10.1038/s41598-019-56185-5.
[20] HUANG C Y, LEE C C, YANG H C, et al. Radiomics as prognostic factor in brain metastases treated with Gamma Knife radiosurgery[J]. J Neurooncol, 2020, 146(3): 439-449. DOI: 10.1007/s11060-019-03343-4.
[21] BODALAL Z, TREBESCHI S, NGUYEN-KIM T D L, et al. Radiogenomics: bridging imaging and genomics[J]. Abdom Radiol(NY), 2019, 44(6): 1960-1984. DOI: 10.1007/s00261-019-02028-w.
[22] ABROL S, KOTROTSOU A, SALEM A, et al. Radiomic phenotyping in brain cancer to unravel hidden information in medical images[J]. Top Magn Reson Imaging, 2017, 26(1): 43-53. DOI: 10.1097/RMR.0000000000000117.
[23] JAIN R, POISSON L M, GUTMAN D, et al. Outcome prediction in patients with glioblastoma by using imaging, clinical, and genomic biomarkers: focus on the nonenhancing component of the tumor[J]. Radiology, 2014, 272(2): 484-493. DOI: 10.1148/radiol.14131691.
[24] MACEACHERN S J, FORKERT N D. Machine learning for precision medicine[J]. Genome, 2021, 64(4): 416-425. DOI: 10.1139/gen-2020-0131.
[25] MILLER J J, SHIH H A, ANDRONESI O C, et al. Isocitrate dehydrogenase-mutant glioma: evolving clinical and therapeutic implications[J]. Cancer, 2017, 123(23): 4535-4546. DOI: 10.1002/cncr.31039.
[26] FARES J, KANOJIA D, RASHIDI A, et al. Genes that mediate metastasis across the blood-brain barrier[J]. Trends Cancer, 2020, 6(8): 660-676. DOI: 10.1016/j.trecan.2020.04.007.
[27] GROSSMANN P, STRINGFIELD O, EL-HACHEM N, et al. Defining the biological basis of radiomic phenotypes in lung cancer[J]. eLife, 2017, 6: e23421. DOI: 10.7554/eLife.23421.
[28] LIU Y, KIM J, BALAGURUNATHAN Y, et al. Radiomic features are associated with EGFR mutation status in lung adenocarcinomas[J]. Clin Lung Cancer, 2016, 17(5): 441-448. DOI: 10.1016/j.cllc.2016.02.001.
[29] 冯颖慧,陈晓东,罗泽斌,等.影像组学在非小细胞肺癌基因突变中的应用进展[J].海南医学, 2021, 32(3):372-376. DOI: 10.3969/j.issn.1003-6350.2021.03.027.
[30] GE M X, ZHUANG Y J, ZHOU X L, et al. High probability and frequency of EGFR mutations in non-small cell lung cancer with brain metastases[J]. J Neurooncol, 2017, 135(2): 413-418. DOI: 10.1007/s11060-017-2590-x.
[31] QIU M T, WANG J, XU Y T, et al. Circulating tumor DNA is effective for the detection of EGFR mutation in non-small cell lung cancer: a meta-analysis[J]. Cancer Epidemiol Biomarkers Prev, 2015, 24(1): 206-212. DOI: 10.1158/1055-9965.EPI-14-0895.
[32] MONACO S E, NIKIFOROVA M N, CIEPLY K, et al. A comparison of EGFR and KRAS status in primary lung carcinoma and matched metastases[J]. Hum Pathol, 2010, 41(1): 94-102. DOI: 10.1016/j.humpath.2009.06.019.
[33] LUO J, SHEN L, ZHENG D. Diagnostic value of circulating free DNA for the detection of EGFR mutation status in NSCLC: a systematic review and meta-analysis[J]. Sci Rep, 2014, 4: 6269. DOI: 10.1038/srep06269.
[34] NAIR J K R, SAEED U A, MCDOUGALL C C, et al. Radiogenomic models using machine learning techniques to predict EGFR mutations in non-small cell lung cancer[J]. Can Assoc Radiol J, 2021, 72(1): 109-119. DOI: 10.1177/0846537119899526.
[35] JUNG W S, PARK C H, HONG C K, et al. Diffusion-weighted imaging of brain metastasis from lung cancer: correlation of MRI parameters with the histologic type and gene mutation status[J]. AJNR Am J Neuroradiol, 2018, 39(2): 273-279. DOI: 10.3174/ajnr.A5516.
[36] AHN S J, KWON H, YANG J J, et al. Contrast-enhanced T1-weighted image radiomics of brain metastases may predict EGFR mutation status in primary lung cancer[J]. Sci Rep, 2020, 10(1): 8905. DOI: 10.1038/s41598-020-65470-7.
[37] WANG G Y, WANG B M, WANG Z, et al. Radiomics signature of brain metastasis: prediction of EGFR mutation status[J]. Eur Radiol, 2021, 31(7): 4538-4547. DOI: 10.1007/s00330-020-07614-x.
[38] KARACHALIOU N, MAYO C, COSTA C, et al. KRAS mutations in lung cancer[J]. Clin Lung Cancer, 2013, 14(3): 205-214. DOI: 10.1016/j.cllc.2012.09.007.
[39] WEISS G J, GANESHAN B, MILES K A, et al. Noninvasive image texture analysis differentiates K-ras mutation from pan-wildtype NSCLC and is prognostic[J]. PLoS One, 2014, 9(7): e100244. DOI: 10.1371/journal.pone.0100244.
[40] LE N Q K, KHA Q H, NGUYEN V H, et al. Machine learning-based radiomics signatures for EGFR and KRAS mutations prediction in non-small-cell lung cancer[J]. Int J Mol Sci, 2021, 22(17): 9254. DOI: 10.3390/ijms22179254.
[41] SHIRI I, MALEKI H, HAJIANFAR G, et al. Next-generation radiogenomics sequencing for prediction of EGFR and KRAS mutation status in NSCLC patients using multimodal imaging and machine learning algorithms[J]. Mol Imaging Biol, 2020, 22(4): 1132-1148. DOI: 10.1007/s11307-020-01487-8.
[42] XING P Y, WANG S Z, WANG Q, et al. Efficacy of crizotinib for advanced ALK-rearranged non-small-cell lung cancer patients with brain metastasis: a multicenter, retrospective study in China[J]. Target Oncol, 2019, 14(3): 325-333. DOI: 10.1007/s11523-019-00637-5.
[43] SONG L, ZHU Z C, MAO L, et al. Clinical, conventional CT and radiomic feature-based machine learning models for predicting ALK rearrangement status in lung adenocarcinoma patients[J]. Front Oncol, 2020, 10: 369. DOI: 10.3389/fonc.2020.00369.
[44] XU X Y, HUANG L, CHEN J Y, et al. Application of radiomics signature captured from pretreatment thoracic CT to predict brain metastases in stage III/IV ALK-positive non-small cell lung cancer patients[J]. J Thorac Dis, 2019, 11(11): 4516-4528. DOI: 10.21037/jtd.2019.11.01.
[45] ZHAO S J, HOU D H, ZHENG X M, et al. MRI radiomic signature predicts intracranial progression-free survival in patients with brain metastases of ALK-positive non-small cell lung cancer[J]. Transl Lung Cancer Res, 2021, 10(1): 368-380. DOI: 10.21037/tlcr-20-361.
[46] RIZZO S, PETRELLA F, BUSCARINO V, et al. CT radiogenomic characterization of EGFR, K-RAS, and ALK mutations in non-small cell lung cancer[J]. Eur Radiol, 2016, 26(1): 32-42. DOI: 10.1007/s00330-015-3814-0.
[47] ZHANG T N, XU Z H, LIU G X, et al. Simultaneous identification of EGFR, KRAS, ERBB2, and TP53 mutations in patients with non-small cell lung cancer by machine learning-derived three-dimensional radiomics[J]. Cancers, 2021, 13(8): 1814. DOI: 10.3390/cancers13081814.
[48] CHEN B T, JIN T H, YE N R, et al. Radiomic prediction of mutation status based on MR imaging of lung cancer brain metastases[J]. Magn Reson Imaging, 2020, 69: 49-56. DOI: 10.1016/j.mri.2020.03.002.
[49] CHEN B T, JIN T H, YE N R, et al. Predicting survival duration with MRI radiomics of brain metastases from non-small cell lung cancer[J]. Front Oncol, 2021, 11: 621088. DOI: 10.3389/fonc.2021.621088.